Publication
Article
Pharmacy Times
Legislation requiring the federal government to negotiate with thepharmaceutical industry for lower Medicare Part D drug prices couldbackfire on the program, officials from the Centers for Medicare &Medicaid Services (CMS) warned Congress.
The bill, a key plank in this year's legislative agenda being pushedby congressional Democrats, would not generate any savings at all,testified actuaries from CMS. "Although the bill would require the secretary[of Health and Human Services] to negotiate with drug manufacturersregarding drug prices, the inability to drive market share viathe establishment of a formulary or the development of a preferredtier significantly undermines the effectiveness of this negotiation,"said Paul Spitalnic, director of the Parts C and D Actuarial Group in theOffice of the Actuary. "Manufacturers would have little to gain byoffering rebates that aren't linked to a preferred position of their products,and we assume that they will be unwilling to do so."
A separate report issued by researchers at the GovernmentAccountability Office stopped short of predicting failure. It did, however,raise questions about the feasibility of the plan.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.